IBRX
Immunitybio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.08B
P/E Ratio
—
EPS
$-0.38
Beta
0.06
52W High
$12.43
52W Low
$1.83
50-Day MA
$7.75
200-Day MA
$3.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunitybio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Fundamentals
| Revenue (TTM) | $113.29M |
| Gross Profit (TTM) | $112.53M |
| EBITDA | $-240.60M |
| Operating Margin | -169.00% |
| Return on Equity | 0.00% |
| Return on Assets | -36.20% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $-0.49 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 62.53 |
| EV/Revenue | 68.98 |
| EV/EBITDA | -8.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 407.00% |
| Shares Outstanding | $1.03B |
| Float | $382.34M |
| % Insiders | 63.67% |
| % Institutions | 16.88% |
Analyst Ratings
Consensus ($14.80 target)
1
Strong Buy4
BuyData last updated: 4/8/2026